These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32819976)

  • 1. Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity.
    Flickinger JC; Singh J; Carlson R; Leong E; Baybutt TR; Barton J; Caparosa E; Pattison A; Rappaport JA; Roh J; Zhan T; Bashir B; Waldman SA; Snook AE
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32819976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.
    Snook AE; Baybutt TR; Xiang B; Abraham TS; Flickinger JC; Hyslop T; Zhan T; Kraft WK; Sato T; Waldman SA
    J Immunother Cancer; 2019 Apr; 7(1):104. PubMed ID: 31010434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy.
    Flickinger JC; Staudt RE; Singh J; Carlson RD; Barton JR; Baybutt TR; Rappaport JA; Zalewski A; Pattison A; Waldman SA; Snook AE
    NPJ Vaccines; 2022 Jun; 7(1):61. PubMed ID: 35739202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope.
    Snook AE; Baybutt TR; Hyslop T; Waldman SA
    Hum Gene Ther Methods; 2016 Dec; 27(6):238-250. PubMed ID: 27903079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C.
    Witek M; Blomain ES; Magee MS; Xiang B; Waldman SA; Snook AE
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1188-95. PubMed ID: 24661671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C.
    Snook AE; Magee MS; Marszalowicz GP; Schulz S; Waldman SA
    Cancer Immunol Immunother; 2012 May; 61(5):713-23. PubMed ID: 22057677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GUCY2C-targeted cancer immunotherapy: past, present and future.
    Snook AE; Magee MS; Waldman SA
    Immunol Res; 2011 Dec; 51(2-3):161-9. PubMed ID: 22038530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8
    Xiang B; Baybutt TR; Berman-Booty L; Magee MS; Waldman SA; Alexeev VY; Snook AE
    J Immunol; 2017 May; 198(9):3507-3514. PubMed ID: 28341670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5.
    Onishi R; Ikemoto S; Shiota A; Tsukamoto T; Asayama A; Tachibana M; Sakurai F; Mizuguchi H
    Int J Pharm; 2024 Sep; 662():124480. PubMed ID: 39038719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.
    Sumida SM; Truitt DM; Lemckert AA; Vogels R; Custers JH; Addo MM; Lockman S; Peter T; Peyerl FW; Kishko MG; Jackson SS; Gorgone DA; Lifton MA; Essex M; Walker BD; Goudsmit J; Havenga MJ; Barouch DH
    J Immunol; 2005 Jun; 174(11):7179-85. PubMed ID: 15905562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction.
    Parker AL; White KM; Lavery CA; Custers J; Waddington SN; Baker AH
    Gene Ther; 2013 Dec; 20(12):1158-64. PubMed ID: 24005577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA.
    Gabitzsch ES; Xu Y; Balint JP; Hartman ZC; Lyerly HK; Jones FR
    Cancer Immunol Immunother; 2010 Jul; 59(7):1131-5. PubMed ID: 20361185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C.
    Flickinger JC; Singh J; Yarman Y; Carlson RD; Barton JR; Waldman SA; Snook AE
    Front Immunol; 2022; 13():855759. PubMed ID: 35355987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors.
    Greig JA; Buckley SM; Waddington SN; Parker AL; Bhella D; Pink R; Rahim AA; Morita T; Nicklin SA; McVey JH; Baker AH
    Mol Ther; 2009 Oct; 17(10):1683-91. PubMed ID: 19603000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.
    Hrycak CP; Windmann S; Bayer W
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31375593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
    Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
    J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy.
    Yang M; Yang CS; Guo W; Tang J; Huang Q; Feng S; Jiang A; Xu X; Jiang G; Liu YQ
    Cancer Biol Ther; 2017 Nov; 18(11):833-840. PubMed ID: 29144842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.
    Entezari AA; Snook AE; Waldman SA
    Expert Opin Ther Targets; 2021 May; 25(5):335-346. PubMed ID: 34056991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity.
    Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Amalfitano A; Jones FR
    Vaccine; 2009 Oct; 27(46):6394-8. PubMed ID: 19559110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV.
    Xin KQ; Jounai N; Someya K; Honma K; Mizuguchi H; Naganawa S; Kitamura K; Hayakawa T; Saha S; Takeshita F; Okuda K; Honda M; Klinman DM; Okuda K
    Gene Ther; 2005 Dec; 12(24):1769-77. PubMed ID: 16079886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.